Credit: Shutterstock

Big come­back? The Q1 re­port on biotech is in, and there’s been some sput­ter­ing

Deal­For­ma’s Chris Doko­ma­ji­lar has been run­ning the num­bers again and backs up some of the things we were al­ready pret­ty sure about — while rais­ing new …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.